Indole-3-propionic acid protects medium-diversity colitic mice via barrier enhancement preferentially over anti-inflammatory effects
Kristoff Nieves, Kyle L. Flannigan, Elizabeth M. Hughes, Matthew Stephens, Andrew Thorne, Ameline Delanne, Kathryn Strayer, Darasimi Kola-Ilesanmi, S. N. Wickramasinghe, Niloofar Mirzadzare, Grace Baruta, Braedon McDonald, Eduardo R. Cobo, Björn Petri, Sridhar Mani, Simon A. Hirota
Abstract
Indole-3-propionic acid (IPA) is a metabolite produced by the intestinal microbiota that has been shown to elicit beneficial effects in the gastrointestinal (GI) tract that include regulating intestinal barrier function, reducing inflammation, and controlling immune responses that lead to fibrosis. In patients with inflammatory bowel disease (IBD), IPA levels are reduced. In the current study, we found that treating mice with IPA at the peak of intestinal inflammation improved clinical outcomes and disease.